Piramal Pharma
Piramal Pharma reported a transitional FY26 with revenue decline due to inventory destocking in a key on-patent commercial product, subdued biotech funding in H1, and intensified competition in inhalation anesthesia i...
Piramal Pharma vs Ajanta Pharma Q4 FY26
Side-by-side earnings comparison across verified financials, sentiment, risks, and management commentary.
Ajanta Pharma
Ajanta Pharma delivered a strong Q4 FY26 with revenue of ₹1,422 crore (+21% YoY) and PAT of ₹267 crore (+18% YoY).
Result Snapshot
Revenue₹2,752 Cr₹1,422 Cr
PAT₹-9 Cr₹267 Cr
EBITDA Margin—23%
Sentimentneutralbullish
Key Quotes
We're currently anticipating revenue growth in the early to mid teens with EBITDA expected to grow faster than revenue supported by operating leverage.
Our revenue from operations grew by 21%. While margins grew by 18%. Reflecting strong operating performance alongside continued investments to support future growth.